Journal Article Summary
The article investigates how obesity affects the pharmacokinetics (PK) of levonorgestrel-based emergency contraception (LNG-EC), which is crucial because LNG-EC is less effective in obese women. With unintended pregnancies being a significant concern, understanding the factors that influence the efficacy of emergency contraception is vital. Previous studies have indicated that obese women experience a higher failure rate with LNG-EC, which may be linked to how their bodies process the medication differently compared to women with normal body weight.
In this study, researchers conducted a prospective open-label trial with ten healthy women, five with normal body mass index (BMI) and five classified as obese. Each participant received a standard dose of LNG-EC (1.5 mg) during one menstrual cycle, and the obese group received a double dose (3.0 mg) in a subsequent cycle. The findings revealed that the peak serum concentration of LNG was significantly lower in obese women after the standard dose compared to normal BMI women. However, when the obese group received the double dose, their peak levels increased to a range similar to that of normal BMI women, suggesting that a higher dose may help overcome the reduced effectiveness associated with obesity.
Despite these promising results, the study has limitations, including a small sample size and the absence of data on the actual effectiveness of the higher dose in preventing pregnancy. Readers should be aware that while doubling the dose of LNG-EC appears to improve drug levels in obese women, further research is necessary to confirm its effectiveness in preventing ovulation and unintended pregnancies. It is advisable for patients to discuss their weight and contraceptive options with a healthcare professional, especially if they are considering using emergency contraception.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Edelman Alison B, Cherala Ganesh, Blue Steven W, Erikson David W, Jensen Jeffrey T. Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. Contraception 2016. DOI: 10.1016/j.contraception.2016.03.006. PMID: 27000996. PMCID: PMC4944814.
Featured Pill Pals Product
My Way (Levonorgestrel) 1.5 mg Tablet - Generic For Plan B and Morning After Pill --- Lupin Pharma --- Over The Counter
My Way (Levonorgestrel) 1.5 mg Tablet ā Generic For Plan B and Morning After Pill ā Lupin Pharma ā Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
